Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Effect of 2 week oral dosing of aliskiren hemifumarate at 50 mg.Kg-1 level on hematological parameter values in female Callithrix jacchus
Assay data:1 Tested
Summary
Effect of 2 week oral dosing of aliskiren hemifumarate at 10 mg.Kg-1 level on hematological parameter values in female Callithrix jacchus
Effect of 2 week oral dosing of aliskiren hemifumarate at 100 mg.Kg-1 level on hematological parameter values in male Callithrix jacchus
Effect of 2 week oral dosing of aliskiren hemifumarate at 50 mg.Kg-1 level on hematological parameter values in male Callithrix jacchus
Effect of 2 week oral dosing of aliskiren hemifumarate at 10 mg.Kg-1 level on hematological parameter values in male Callithrix jacchus
Displacement of [3H]GR205171 from marmoset cerebral striatum NK1 receptor after 60 mins by scintillation counting analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Plasma concentration in marmoset at 0.03 mg/kg, sc measured 15 to 105 mins post-dose
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Anxiolytic activity in marmoset human threat test model assessed as reduction in number of postures at 10 mg/kg, po preincubated for 1 hr followed by compound wash out for 3 days relative to vehicle-treated control
SummaryPubMed Citation
Anxiolytic activity in po dosed marmoset human threat test model assessed as reduction in number of postures preincubated for 1 hr followed by compound wash out for 3 days
Anxiolytic activity in marmoset human threat test model assessed as reduction in number of postures at 0.3 mg/kg, po preincubated for 1 hr followed by compound wash out for 3 days relative to vehicle-treated control
Anxiolytic activity in marmoset human threat test model assessed as reduction in number of postures at 1 mg/kg, po preincubated for 1 hr followed by compound wash out for 3 days relative to vehicle-treated control
Anxiolytic activity in marmoset human threat test model assessed as reduction in number of postures at 3 mg/kg, po preincubated for 1 hr followed by compound wash out for 3 days relative to vehicle-treated control
Plasma concentration in marmoset at 0.03 g/kg, sc after 15 mins
Plasma concentration in marmoset at 0.03 g/kg, sc after 105 mins
Plasma concentration in marmoset at 0.03 g/kg, sc after 60 mins
Inhibition of human alphaCGRP-induced increase in facial blood flow in marmoset at 0.03 mg/kg, sc administered 30 mins after human alphaCGRP-challenge measured 15 mins post-dose by laser Doppler flowmetric analysis relative to control
Inhibition of human alphaCGRP-induced increase in facial blood flow in marmoset at 0.03 mg/kg, sc administered 30 mins after human alphaCGRP-challenge measured 60 mins post-dose by laser Doppler flowmetric analysis relative to control
Inhibition of human alphaCGRP-induced increase in facial blood flow in marmoset at 0.03 mg/kg, sc administered 30 mins after human alphaCGRP-challenge measured 105 mins post-dose by laser Doppler flowmetric analysis relative to control
Plasma concentration in Harlan marmoset at 7 mg/kg, sc at 15 mins
Plasma concentration in Harlan marmoset at 7 mg/kg, sc after 60 to 105 mins
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on